Skip to main content
Contact Locations Diversity Pro Bono Why Wolf

Two Wolf Greenfield Attorneys Recognized Among World’s Leading IP Strategists

3 min read

Two Wolf Greenfield shareholders have been included in the 2025 edition of the IAM Strategy 300: The World’s Leading IP Strategists. This guide highlights leading practitioners who are elevating IP portfolio management and litigation strategy by developing and implementing approaches that maximize both competitive advantage and the business value of IP assets. Those recognized come from service providers, corporations, research institutions, and universities.

Scott focuses his practice on post-grant patent counseling and litigation matters at the US Patent and Trademark Office (USPTO) and related appeals to the US Court of Appeals for the Federal Circuit (CAFC). Scott handles all aspects of post-issuance patent proceedings, with a particular focus on administrative trials before the Patent Trial and Appeal Board (PTAB), such as inter partes review (IPR), post-grant review (PGR), and patent reexamination. He also provides advice on USPTO post-grant proceedings concurrent with complex International Trade Commission (ITC) and district court litigations. Scott is one of the most active PTAB trial attorneys in the US, having handled more than 500 PTAB matters, including competitor disputes in which significant market share/damage liability was at stake (e.g., $500 million+). He currently serves as lead post-grant counsel to some of the world’s best-known innovators. Scott also serves as an adjunct professor at the George Washington University School of Law in Washington, DC.  

Rob develops strategies for life science companies to maximize exclusivity for therapeutic and diagnostic products. He assists clients with building global patent portfolios aligned with product life cycle, and advises clients on regulatory exclusivities, patent term extensions, Orange Book listings, and biosimilars. In addition to pharma and biotech companies, Rob works with universities, research institutions, and venture capital investors, providing patentability and freedom-to-operate assessments, non-infringement and invalidity opinions, performing IP diligence, and preparing agreements. He regularly counsels federal grant recipients and contractors with Bayh-Dole compliance, including use of iEdison. Rob has worked extensively in technologies including antibodies, vaccines, chimeric antigen receptors, cell therapies, synthetic biology, medical devices, imaging agents, biologics, and small molecules for new disease indications.

The IAM Strategy 300 highlights leading IP strategists worldwide, selected through confidential nominations, in-depth interviews, and peer review. To qualify, individuals must be nominated by at least three professionals from outside their organization and demonstrate exceptional skill and insight in the creation, development, and management of IP value.
Top